Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 3, 2008, Pages 928-941

  Ory, B ^a,b   Moriceau, G ^a,b   Trichet, V ^a,b   Blanchard, F ^a,b   Berreur, M ^a,b   Redini F ^a,b   Rogers, M ^c   Heymann, D ^a,b,d,e  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d Hospital   (France)

^e Universite de Nantes   (France)

Author keywords

Bisphosphonate; Farnesyl diphosphate synthase; Metabolic resistance; Osteosarcoma; Zoledronic acid

Indexed keywords

RATTUS;

EID: 44149099089     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00141.x     Document Type: Article

References (50)

1. 1 Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high‐grade osteosarcoma of the extremity. Updated results of the Multi‐Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991: 8–14.
2. 2 Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976 ; 37: 1–11.
3. 3 Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS. Treatment of nonmetastat‐ic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997 ; 15: 76–84.
4. 4 Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med. 2004 ; 10: 337–43.
5. 5 Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000 ; 88: 2961–78.
6. 6 Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003 ; 9: 2643–58.
7. 7 Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007 ; 119: S150–62.
8. 8 Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein ger‐anylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI‐298. J Bone Miner Res. 2000 ; 15: 1467–76.
9. 9 Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106‐01 clonal rat osteosarco‐ma cell line. Br J Cancer. 2001 ; 84: 951–8.
10. 10 Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann Wvan Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosar‐coma cell growth in vitro. Anticancer Drugs. 2001 ; 12: 459–65.
11. 11 Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005 ; 37: 74–86.
12. 12 Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metas‐tases and prolongs overall survival of osteosarcoma‐bearing mice. Cancer. 2005 ; 104: 2522–9.
13. 13 Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D. Zoledronic acid activates the DNA S‐phase checkpoint and induces osteosarcoma cell death characterized by apoptosis‐inducing factor and endonuclease‐G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007 ; 71: 333–43.
14. 14 Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002 ; 53: 615–27.
15. 15 Gottesman MM, Ambudkar SV, Ni B, Aran JM, Sugimoto Y, Cardarelli CO, Pastan I. Exploiting multidrug resistance to treat cancer. Cold Spring Harb Symp Quant Biol. 1994 ; 59: 677–83.
16. 16 Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006 ; 580: 2903–9.
17. 17 Jasmin C, Allouche M, Jude JG, Klein B, Thiery JP, Perdereau B, Gongora R, Gongora G, Mazabraud A. An experimental model of osteosarco‐mas in rats. Sem Hop. 1982 ; 58: 1684–9.
18. 18 Klein B, Pals S, Masse R, Lafuma J, Morin M, Binart N, Jasmin JR, Jasmin C. Studies of bone and soft‐tissue tumours induced in rats with radioactive cerium chloride. Int J Cancer. 1977 ; 20: 112–9.
19. 19 Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone. 2003 ; 33: 216–28.
20. 20 Biedler JL, Riehm H. Cellular resistance to actino‐mycin D in Chinese hamster cells in vitro: cross‐resistance, radioautographic, and cytogenetic studies. Cancer Res. 1970 ; 30: 1174–84.
21. 21 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993 ; 62: 385–427.
22. 22 Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cyto‐toxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 ; 41: 1967–72.
23. 23 Gibbs JB, Oliff A. The potential of farnesyltrans‐ferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol. 1997 ; 37: 143–66.
24. 24 Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, Rogers MJ. Nitrogen‐containing bisphosphonates induce apoptosis of Caco‐2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate‐induced gastrointestinal toxicity. Bone. 2001 ; 29: 336–43.
25. 25 Reszka AA, Halasy‐Nagy J, Rodan GA. Nitrogen‐bis‐phosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol. 2001 ; 59: 193–202.
26. 26 Kruh GD. Introduction to resistance to anticancer agents. Oncogene. 2003 ; 22: 7262–4.
27. 27 Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006 ; 6: 307–12.
28. 28 Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG. Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology. 2004 ; 67: 351–8.
29. 29 Ortiz‐Gomez A, Jimenez C, Estevez AM, Carrero‐Lerida J, Ruiz‐Perez LM, Gonzalez‐Pacanowska D. Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overex‐pression confers resistance to risedronate. Eukaryot Cell. 2006 ; 5: 1057–64.
30. 30 Van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 2003 ; 33: 805–11.
31. 31 Salomo M, Jurlander J, Nielsen LB, Gimsing P. How myeloma cells escape bisphosphonate‐mediated killing: development of specific resistance with preserved sensitivity to conventional chemothera‐peutics. Br J Haematol. 2003 ; 122: 202–10.
32. 32 Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensi‐tivity. Cancer. 2003 ; 98: 1958–66.
33. 33 Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her‐2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol. 2003 ; 25: 27–32.
34. 34 Papapoulos SE, Eekhoff EM, Zwinderman AH. Acquired Resistance to Bisphosphonates in Paget's Disease of Bone. J Bone Miner Res. 2006 ; 21: P88–91.
35. 35 Endo A. The discovery and development of HMG‐CoA reductase inhibitors. J Lipid Res. 1992 ; 33: 1569–82.
36. 36 Doggrell SA. Statins in the 21st century: end of the simple story? Expert Opin Investig Drugs. 2001 ; 10: 1755–66.
37. 37 Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006 ; 6: 1075–85.
38. 38 Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999 ; 341: 342–52.
39. 39 Sandberg AA, Bridge JA. Updates on the cytoge‐netics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet. 2003 ; 145: 1–30.
40. 40 Benassi MS, Molendini L, Gamberi G, Ragazzini P, Sollazzo MR, Merli M, Asp J, Magagnoli G, Balladelli A, Bertoni F, Picci P. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 1999 ; 84: 489–93.
41. 41 David JP, Mehic D, Bakiri L, Schilling AF, Mandic V, Priemel M, Idarraga MH, Reschke MO, Hoffmann O, Amling M, Wagner EF. Essential role of RSK2 in c‐Fos‐dependent osteosarcoma development. J Clin Invest. 2005 ; 115: 664–72.
42. 42 Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, Ladanyi M. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer. 1999 ; 80: 199–204.
43. 43 Grem JL, King SA, Wittes RE, Leyland‐Jones B. The role of methotrexate in osteosarcoma. J Natl Cancer Inst. 1988 ; 80: 626–55.
44. 44 Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003 ; 22: 7265–79.
45. 45 Beretta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F, Perego P. Cellular pharmacology of cis‐platin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin‐sensitive and ‐resistant cells. Biochem Pharmacol. 2004 ; 68: 283–91.
46. 46 Gomes CM, Van Paassen H, Romeo S, Welling MM, Feitsma RI, Abrunhosa AJ, Botelho MF, Hogendoorn PC, Pauwels E, Cleton‐Jansen AM. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines:mRNA analysis and functional radiotracer studies. Nucl Med Biol. 2006 ; 33: 831–40.
47. 47 Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S. May P‐glycoprotein status be used to stratify high‐grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol. 2006 ; 29: 1459–68.
48. 48 Lourda M, Trougakos IP, Gonos ES. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up‐regulation of Clusterin/Apolipoprotein J. Int J Cancer. 2007 ; 120: 611–22.
49. 49 Mensah‐Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, Baker LH. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 ; 109: 957–65.
50. 50 Ory B, Moriceau, G, Redini, F, Heymann, D. mTOR inhibitors (rapamycin and their derivatives) and nitrogen bisphosphonates: bi‐functional conpounds for the treatment of bone tumors. Curr Med Chem. 2007 ; 14: 1381–7.